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Abstract
Recent work by Böttcher and colleagues defines a new role for Natural Killer cells in the anti-tumor immune response,
arriving early into the tumor microenvironment before passing the baton to DC1 dendritic cells. DC1 dendritic cells
subsequently activate CD8+ T cells resulting in effective anti-tumor immunity. This work highlights the cooperative
nature of anti-tumor immunity set in motion by Natural Killer cells, and immune evasion by tumors through their
exclusion.
Main text
Sustained infiltration of CD8+ T cells into the tumor
microenvironment has been shown to generate an im-
mune suppressive microenvironment through the upregu-
lation of immune inhibitory molecules, including PD-L1
(programmed death receptor ligand 1) on tumor cells or
myeloid cells [1]. Accordingly, the majority of melanoma
patients with a T-cell inflamed tumor microenvironment
responds to checkpoint blockade therapy targeting
immune inhibitory pathways such as PD-1:PD-L1 interac-
tions, while non-T cell-inflamed tumors tend to be refrac-
tory to this therapy [2]. Unraveling the cellular and
molecular determinants of T cell recruitment to and
retention in solid tumors is therefore a crucial step toward
improving existing immunotherapies.
Antigen-presenting cells, in particular dendritic cells
(DC), are known to orchestrate initial activation of T cells
in the tumor-draining lymph node [1]. In particular,
cross-presenting CD103+ DC (also known as DC1 or
Clec9a + DC) appear to be critical for priming CD8+ T
cells [3]. Recent reports have defined a distinct role for
CD103+ DC residing within the tumor microenviron-
ment, where they cooperate with CD8+ cytotoxic T cells
to recognize and clear tumor cells. Consequently, tumors
able to exclude CD103+ DC can successfully evade T-cell
mediated immune control [4, 5]. However, our
understanding of the recruitment and retention of
tumor-resident DC populations is still sparse.
Böttcher et al. addressed this question using a melan-
oma tumor model previously reported to exclude T cells
and CD103+ DC through the upregulation of cyclooxy-
genase enzymes COX-1 and COX-2 (encoded by ptgs1
and ptgs2) and their catalytic product, prostaglandin E2
(PGE2) [6]. In addition to the exclusion of CD103+ DC,
they observed a stark reduction in the recruitment of
Natural Killer (NK) cells into tumors [7]. Assessing the
chemokine expression profile of tumor-residing immune
cell subsets, the authors showed that XCL1 is produced
exclusively by NK cells while CCL5 is secreted by both
NK cells and CD8+ effector T cells. Both XCL1 and
CCL5 as well as CCL4 have previously been reported to
attract CD103+ DC to inflammatory sites through binding
to XCR1/CCR5 chemokine receptors [4, 8], results that
were confirmed in this study. In contrast to observations
by Böttcher et al., however, previous studies found chemo-
kine production originated from non-immune cells, sug-
gesting that the source for chemokines might be highly
context dependent.
Depletion of NK cells resulted in failed recruitment of
CD103+ DC and immune evasion by tumors. In vitro ana-
lysis showed that tumor-derived PGE2 resulted in dimin-
ished secretion of CCL5 and XCL1 by NK cells and
increased NK cell death [7]. The observation of increased
lymphocyte death in tumors with high levels of PGE2
agrees with previous reports. A study of ovarian cancer
found that COX-2/PGE2 signaling caused increased
expression of Fas-ligand on endothelial cells, which in
turn increased apoptosis of infiltrating T cells and resulted
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in a non-T cell-inflamed tumor microenvironment [9].
Both studies show a cell death-related phenotype, however
since NK cell death was observed ex vivo, the molecular
mechanism appear to be distinct and should be fully
elucidated.
The authors then validated their findings using patient
samples and found that indeed NK cells are the domin-
ant source of XCL1/2, while CD8+ effector T cells pro-
duce high levels of CCL5. Using human RNA transcript
data, the authors provide further evidence supporting
the concept that NK cells recruit CD103+ DC, which in
turn are required for the recruitment of effector T cells.
Previous work has shown that CD103+ DC are critical
for the recruitment of effector T cells into the tumor
microenvironment through the secretion of CXCL9 and
CXCL10 [5, 6]. Likewise, these studies provided evidence
that restoration of CD103+ DC infiltration mediates
regained responsiveness to immunotherapy.
Considering these observations in conjunction with
those made by Böttcher and colleagues, it is plausible to
suggest that anti-tumor immunity may operate as a relay
race in which immune cells recruit each other to pass
the tumor-reactive “baton” (See Fig. 1). Such cooperation
ensures the sequential recruitment of NK cells, CD103+
DC, and most importantly CD8+ effector T cells into the
tumor microenvironment. It is worth noting that, similar
to effector T cells, NK cells can also be recruited by
CXCL9 and CXCL10.
Meanwhile, CD8+ effector T cells are also a source
of CCL4, CCL5 and XCL1. This redundancy in
chemokine-mediated immune cell recruitment sug-
gests a strong positive feedback loop, and highlights
the importance of the recruitment and activation of
early effector cells such as NK cells.
The canonical cytolytic role of NK cells can directly or
indirectly contribute to tumor control.
However, Böttcher et al. make several intriguing observa-
tions regarding the role of NK cells during an anti-tumor
immune response that go beyond their classically described
function. The intriguing notion that innate lymphocytes
can be recruited into the tumor at very early stages could
explain the recruitment of CD103+ DC into tumors lacking
chemokine production. In conjunction with the observation
that PGE2 inhibits NK cell function, it could therefore be
speculated that PGE2 mediates inhibition of anti-tumor im-
mune responses at early stages of tumor development. In-
deed, expression of cyclooxygenases and production of
PGE2 has been linked to malignant transformation in mul-
tiple tissues and therefore is an early event in tumor devel-
opment [10]. However, additional studies will be
needed to elucidate how NK cells are activated and
recruited into early tumor lesions. Similarly, whether
NK cell activation is required in all cancer types to
drive recruitment and retention of CD103+ DC and
CD8+ effector T cells merits further investigation.
Determining the mechanism of NK cell recruitment
could potentially lead to direct targeting of NK cell
recruitment as a therapeutic target to start the
tumor-immune “relay race.” This therapeutic approach
could convert immunotherapy-resistant, non-T
cell-inflamed tumors into checkpoint blockade
therapy-sensitive T cell-inflamed microenvironments,
potentially independent of the tumor type and
molecular mechanism for exclusion of CD103+ DC
and CD8+ T cells.
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Fig. 1 The tumor-immune relay race. Natural Killer (NK) cells are the
first to arrive in the tumor microenvironment and recruit CD103+
dendritic cells (DC) through the secretion of chemokines. Activated
DC then transport antigen from the tumor to the tumor-draining
lymph node where they prime T cells (T). DC residence in tumors is
also critical to drive effector T cell recruitment into the tumor
microenvironment. Sensing and eradication of tumors is thus the
result of collaboration of distinct cell types within the
tumor microenvironment
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